Advanced Search

 

Study ID Status Title Patient Level Data
347414/008 Completed Study to assess immunogenicity and safety of GSK Biologicals’ investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals’ DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age Study Listed on ClinicalStudyDataRequest.com
347414/010 Terminated Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life. Study Listed on ClinicalStudyDataRequest.com
347414/016 Completed A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to infants in their thirth, fourth and fifth months of life, with concomitant administration of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine Study Listed on ClinicalStudyDataRequest.com
347414/017 Completed A multinational, randomised, controlled, single-blind, phase-II study to evaluate the safety and immunogenicity of two investigational vaccination regimens versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix) given concomitantly with DTPw-HBV vaccine in a separate injection of DTPw-HBV to infants at 2, 4, and 6 months of age Study Listed on ClinicalStudyDataRequest.com
347414/020 Completed A Phase III, randomized, single blind study to assess the immune response induced by Prevenar™(Wyeth Lederle) when administered to healthy infants with DTPa-HBV-IPV/Hib, compared to an investigational vaccination regimen as a 3-dose primary vaccination course at a monthly interval starting at 8–16 Weeks of age Study Listed on ClinicalStudyDataRequest.com
347414/023 Completed A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age. Study Listed on ClinicalStudyDataRequest.com
347414/026 Completed A Phase III, randomized single-blind clinical trial to assess the immune memory induced by an investigational vaccination regimen in comparison with Prevnar and the immune response to a fourth dose of the pneumococcal vaccine and the investigational vaccination regimen, when admininistered to healthy children (12-15 Months) Study Listed on ClinicalStudyDataRequest.com
347414/028 Completed A randomized, controlled, open, phase-II clinical study to evaluate the safety and immunogenicity of an experimental formulation extemporaneously mixed with SmithKline Beecham Biologicals' Haemophilus influenzae type b (Hib) vaccine, administered as a booster dose with DTPa-HBV-IPV to healthy children 12 to 18 months old Study Listed on ClinicalStudyDataRequest.com
347414/029 Completed Multinational, randomised, controlled, open, phase 2 clinical study to evaluate the safety and immunogenicity of GSK Biologicals’ investigational vaccination regimen administered as a booster dose to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study 347414/017 Study Listed on ClinicalStudyDataRequest.com
347414/035 Completed A phase-III, open, controlled, follow-up clinical trial, with Prevenar as control, to assess the safety of GSK Biologicals’ investigational vaccination regimen administered with DTPa-HBV-IPV/Hib to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study in the Netherlands Study Listed on ClinicalStudyDataRequest.com
347414/036 Completed A phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Biologicals’ investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study 347414/023 Study Listed on ClinicalStudyDataRequest.com
371594/006 Completed A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen, to healthy toddlers primed in study 371594/004. Study Listed on ClinicalStudyDataRequest.com
385/004 Completed Randomized, 2-way crossover, bioequivalence study of tranylcypromine sulfate 10mg tablets: Parnate® film-coated tablets of GlaxoSmithKline USA and Parnate® sugar-coated tablets of GlaxoSmithKline Canada administered as 1 x 10mg film-coated tablet or sugar-coated tablet…
393229/005 Completed Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma
393229/007 Completed PHASE II MULTICENTER STUDY OF IODINE-131 ANTI-B1 ANTIBODY CONSOLIDATION FOR PATIENTS WITH DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA FOLLOWING FIRST-LINE CHOP Study Listed on ClinicalStudyDataRequest.com
393229/010 Completed Retreatment Study of Patients with Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody Study Listed on ClinicalStudyDataRequest.com
393229/023 Completed Fludarabine monophosphate followed by Iodine I 131 Tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma Study Listed on ClinicalStudyDataRequest.com
393229/027 Completed A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma Study Listed on ClinicalStudyDataRequest.com
393229/028 Completed A Multi-Center, Randomized, Phase 3 Study of Rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Study Listed on ClinicalStudyDataRequest.com
393229/028 Completed A Multi-Center, Randomized, Phase 3 Study of Rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Study Listed on ClinicalStudyDataRequest.com
393229/032 Completed A single arm, open-label, multicentre, phase II study of Tositumomab and Iodine 131-Tositumomab in subjects with indolent non-Hodgkin's Lymphoma who have previously received Rituximab.
402764/004 Completed A phase III, open, randomized study to evaluate the immunogenicity and reactogenicity of investigational vaccination regimens Study Listed on ClinicalStudyDataRequest.com
402764-003 Completed A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen given to healthy toddlers primed in study 402764-001
404 Completed Effect of chronic Wellbutrin SR administration on craving, withdrawal, and impairment of cognitive performance associated with nicotine abstinence.
404286/006 Completed A phase II, open, randomized, controlled study to assess the immune memory induced by an investigational vaccination regimen and the safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen in toddlers primed in study 404286/001. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.